Evidence map›Paper›PMID 39043728›Full record

ArticleNature communications2024

Author Correction: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Xia Sheng, Hatice Zeynep Nenseth, Su Qu, Omer F Kuzu, Turid Frahnow, Lukas Simon, Stephanie Greene, Qingping Zeng, Ladan Fazli, Paul S Rennie and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Xia ShengDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway.
Hatice Zeynep NensethDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway.
Su QuDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway.
Omer F KuzuDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway.
Turid FrahnowInstitute of Computational Biology, Helmholtz Zentrum München, 85764, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-3264-6039
Lukas SimonInstitute of Computational Biology, Helmholtz Zentrum München, 85764, Neuherberg, Germany.ORCID http://orcid.org/0000-0001-6148-8861
Stephanie GreeneFosun Orinove, Inc., Unit 211, Building A4, 218 Xinhu Street, 215000, SuZhou, China.
Qingping ZengFosun Orinove, Inc., Unit 211, Building A4, 218 Xinhu Street, 215000, SuZhou, China.
Ladan FazliThe Vancouver Prostate Centre, Vancouver, BC V6H3Z6, Canada.
Paul S RennieThe Vancouver Prostate Centre, Vancouver, BC V6H3Z6, Canada.
Ian G MillsMovember/PCUK Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology (CCRCB), Queen's University of Belfast, Belfast, BT7 1NN, UK.
Håvard DanielsenInstitute for Cancer Genetics and Informatics, Oslo University Hospital, 0379, Oslo, Norway.
Fabian TheisInstitute of Computational Biology, Helmholtz Zentrum München, 85764, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-2419-1943
John B PattersonFosun Orinove, Inc., Unit 211, Building A4, 218 Xinhu Street, 215000, SuZhou, China.
Yang JinDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway. yang.jin@ibv.uio.no.
Fahri SaatciogluDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway. fahris@ibv.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39043728
PMCPMC11266509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.